ketoconazole and incb-018424

ketoconazole has been researched along with incb-018424 in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, X; Emm, T; Landman, RR; Lo, Y; McGee, RF; McKeever, EG; Punwani, NG; Scherle, PA; Shi, JG; Williams, WV; Yeleswaram, S	1
Fraczkiewicz, G; Shi, JG; Williams, WV; Yeleswaram, S	1
Aslanis, V; He, H; Heimbach, T; Huth, F; Jin, Y; Schiller, H; Umehara, K	1

Trials

1 trial(s) available for ketoconazole and incb-018424

Article	Year
The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. Journal of clinical pharmacology, 2012, Volume: 52, Issue:6 Topics: Adult; Antineoplastic Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Induction; Enzyme Inhibitors; Erythromycin; Female; Half-Life; Humans; Janus Kinase 1; Janus Kinase 2; Ketoconazole; Male; Metabolic Detoxication, Phase I; Middle Aged; Nitriles; Phosphorylation; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Rifampin; STAT3 Transcription Factor; Young Adult	2012

Article

Year

The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers.

Journal of clinical pharmacology, 2012, Volume: 52, Issue:6

Topics: Adult; Antineoplastic Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Induction; Enzyme Inhibitors; Erythromycin; Female; Half-Life; Humans; Janus Kinase 1; Janus Kinase 2; Ketoconazole; Male; Metabolic Detoxication, Phase I; Middle Aged; Nitriles; Phosphorylation; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Rifampin; STAT3 Transcription Factor; Young Adult

2012

Other Studies

2 other study(ies) available for ketoconazole and incb-018424

Article	Year
Predicting drug-drug interactions involving multiple mechanisms using physiologically based pharmacokinetic modeling: a case study with ruxolitinib. Clinical pharmacology and therapeutics, 2015, Volume: 97, Issue:2 Topics: Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Digoxin; Drug Interactions; Erythromycin; Fasting; Fluconazole; Humans; Ketoconazole; Models, Biological; Nitriles; Prospective Studies; Pyrazoles; Pyrimidines; Retrospective Studies; Rifampin	2015
Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions. Drug metabolism and personalized therapy, 2019, 05-30, Volume: 34, Issue:2 Topics: Administration, Oral; Caco-2 Cells; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Drug Interactions; Erythromycin; Humans; Ketoconazole; Models, Biological; Nitriles; Pyrazoles; Pyrimidines; Rifampin	2019

Article

Year

Predicting drug-drug interactions involving multiple mechanisms using physiologically based pharmacokinetic modeling: a case study with ruxolitinib.

Clinical pharmacology and therapeutics, 2015, Volume: 97, Issue:2

Topics: Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Digoxin; Drug Interactions; Erythromycin; Fasting; Fluconazole; Humans; Ketoconazole; Models, Biological; Nitriles; Prospective Studies; Pyrazoles; Pyrimidines; Retrospective Studies; Rifampin

2015

Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.

Drug metabolism and personalized therapy, 2019, 05-30, Volume: 34, Issue:2

Topics: Administration, Oral; Caco-2 Cells; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Drug Interactions; Erythromycin; Humans; Ketoconazole; Models, Biological; Nitriles; Pyrazoles; Pyrimidines; Rifampin

2019